Caribou Biosciences, Inc. Basic Shares Outstanding (Weighted Average)
Caribou Biosciences, Inc. (CRBU) reported Basic Shares Outstanding (Weighted Average) of 100.99 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-13
- Caribou Biosciences, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 100.99M shares, a 8.55% increase year-over-year.
- Caribou Biosciences, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 95.86M shares, a 3.43% increase year-over-year.
- Caribou Biosciences, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 94.55M shares, a 3.71% increase year-over-year.
- Caribou Biosciences, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 93.29M shares, a 3.14% increase year-over-year.
- Caribou Biosciences, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 93.39M shares, a 3.40% increase from fiscal 2024.
- Caribou Biosciences, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 90.32M shares, a 22.37% increase from fiscal 2023.
- Caribou Biosciences, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 73.81M shares, a 21.39% increase from fiscal 2022.
- Caribou Biosciences, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 60.80M shares, a 92.02% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 100.99M shares 10-Q · filed 2026-08-13 | 98.44M shares 10-Q · filed 2026-08-13 | 97.13M shares derived: average of 3 quarters · filed 2026-08-13 | 96.17M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 95.86M shares 10-Q · filed 2026-05-07 | 95.21M shares derived: average of 2 quarters · filed 2026-05-07 | 94.57M shares derived: average of 3 quarters · filed 2026-05-07 | 94.18M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 94.55M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 93.92M shares derived: average of 2 quarters · filed 2026-03-05 | 93.62M shares derived: average of 3 quarters · filed 2026-08-13 | 93.39M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 93.29M shares 10-Q · filed 2025-11-12 | 93.16M shares derived: average of 2 quarters · filed 2026-08-13 | 93.00M shares 10-Q · filed 2025-11-12 | 92.54M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 93.03M shares 10-Q · filed 2026-08-13 | 92.86M shares 10-Q · filed 2026-08-13 | 92.29M shares derived: average of 3 quarters · filed 2026-08-13 | 91.83M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 92.68M shares 10-Q · filed 2026-05-07 | 91.92M shares derived: average of 2 quarters · filed 2026-05-07 | 91.43M shares derived: average of 3 quarters · filed 2026-05-07 | 91.16M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 91.17M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 90.81M shares derived: average of 2 quarters · filed 2026-03-05 | 90.65M shares derived: average of 3 quarters · filed 2026-03-05 | 90.32M shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 90.46M shares 10-Q · filed 2025-11-12 | 90.40M shares derived: average of 2 quarters · filed 2025-11-12 | 90.03M shares 10-Q · filed 2025-11-12 | 89.67M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 90.34M shares 10-Q · filed 2025-08-12 | 89.82M shares 10-Q · filed 2025-08-12 | 89.41M shares derived: average of 3 quarters · filed 2025-08-12 | 88.01M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 89.30M shares 10-Q · filed 2025-05-08 | 88.95M shares derived: average of 2 quarters · filed 2025-05-08 | 87.23M shares derived: average of 3 quarters · filed 2025-05-08 | 80.77M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 88.59M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 86.19M shares derived: average of 2 quarters · filed 2025-03-10 | 77.93M shares derived: average of 3 quarters · filed 2025-03-10 | 73.81M shares 10-K · filed 2025-03-10 |
| 2023-09-30 | 83.78M shares 10-Q · filed 2024-11-06 | 72.60M shares derived: average of 2 quarters · filed 2024-11-06 | 68.88M shares 10-Q · filed 2024-11-06 | 66.85M shares derived: average of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | 61.42M shares 10-Q · filed 2024-08-06 | 61.30M shares 10-Q · filed 2024-08-06 | 61.20M shares derived: average of 3 quarters · filed 2024-08-06 | 61.13M shares derived: average of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | 61.19M shares 10-Q · filed 2024-05-07 | 61.10M shares derived: average of 2 quarters · filed 2024-05-07 | 61.03M shares derived: average of 3 quarters · filed 2024-05-07 | 60.96M shares derived: average of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | 61.01M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 60.95M shares derived: average of 2 quarters · filed 2024-03-11 | 60.88M shares derived: average of 3 quarters · filed 2024-03-11 | 60.80M shares 10-K · filed 2024-03-11 |
| 2022-09-30 | 60.89M shares 10-Q · filed 2023-11-07 | 60.82M shares derived: average of 2 quarters · filed 2023-11-07 | 60.73M shares 10-Q · filed 2023-11-07 | 60.67M shares derived: average of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | 60.76M shares 10-Q · filed 2023-08-08 | 60.65M shares 10-Q · filed 2023-08-08 | 60.60M shares derived: average of 3 quarters · filed 2023-08-08 | 56.92M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 60.55M shares 10-Q · filed 2023-05-09 | 60.52M shares derived: average of 2 quarters · filed 2023-05-09 | 55.64M shares derived: average of 3 quarters · filed 2023-05-09 | 44.30M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 60.49M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 53.19M shares derived: average of 2 quarters · filed 2023-03-09 | 38.88M shares derived: average of 3 quarters · filed 2023-03-09 | 31.66M shares 10-K · filed 2023-03-09 |
| 2021-09-30 | 45.89M shares 10-Q · filed 2022-11-08 | 28.08M shares derived: average of 2 quarters · filed 2022-11-08 | 22.05M shares 10-Q · filed 2022-11-08 | |
| 2021-06-30 | 10.26M shares 10-Q · filed 2022-08-09 | 9.88M shares 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |